Cyclophosphamide: all 1,616 studies that test it
Page 10 of 17. Open to participants first (256), then studies with results posted, then the rest; newest registration first within each.
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaActive, not recruitingNCT03914625Phase 3
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant CyclophosphamideActive, not recruitingNCT03910452Early Phase 1
- A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeActive, not recruitingNCT03899337Phase 2
- Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast CancerCompletedNCT03888677Phase 3
- A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsTerminatedNCT03861403Phase 1
- 'ADVANCE' (A Pilot Trial)Active, not recruitingNCT03858322Phase 1
- Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell LymphomaStatus unknownNCT03853044Phase 2
- Targeting the Tumor Microenvironment in R/M SCCHNStatus unknownNCT03844763Phase 1/2
- DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
- Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid TumorsActive, not recruitingNCT03836352Phase 2
- Autologous Transplant To End NMO Spectrum DisorderWithdrawnNCT03829566Phase 2/3
- A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)Active, not recruitingNCT03821610Phase 2
- The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian CancerStatus unknownNCT03814447Early Phase 1
- MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian CancerStatus unknownNCT03799913Early Phase 1
- BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's LymphomaCompletedNCT03794167Phase 2
- Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung DiseaseStatus unknownNCT03770663Phase 3
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Active, not recruitingNCT03755804Phase 2
- Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast CancerStatus unknownNCT03749850Phase 1
- GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid TumorsCompletedNCT03733587Phase 1
- BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCTStatus unknownNCT03733327Phase 2/3
- Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple MyelomaCompletedNCT03731832Phase 2
- Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple MyelomaStatus unknownNCT03716856Phase 1
- CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple MyelomaSuspendedNCT03710421Phase 1
- Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple MyelomaCompletedNCT03700450Phase 2
- IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerActive, not recruitingNCT03655002Phase 1
- Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AMLStatus unknownNCT03654703Phase 2
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnNCT03647423Phase 1/2
- Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related SarcomasActive, not recruitingNCT03600649Phase 1
- Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid TumorsTerminatedNCT03585465Phase 1/2
- CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
- Liver Transplantation With Tregs at MGHCompletedNCT03577431Phase 1/2
- BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)Active, not recruitingNCT03576378Phase 1/2
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnNCT03574649Phase 2
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnNCT03563170Phase 1/2
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnNCT03563144Phase 2
- Anti-inflammatory Treatment for Inactive Takayasu ArteritisStatus unknownNCT03550781Phase 2/3
- RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis FactorCompletedNCT03536039Phase 2
- T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic AnemiaActive, not recruitingNCT03531736Phase 1
- Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast CancerCompletedNCT03518242Phase 1
- Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)Active, not recruitingNCT03477500Phase 3
- Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT03467386Phase 1
- CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALLActive, not recruitingNCT03467256Phase 1/2
- Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With MyelomaTerminatedNCT03448978Phase 1
- AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaActive, not recruitingNCT03434769Phase 1
- Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT03426969Early Phase 1
- Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid TumorsTerminatedNCT03420963Phase 1
- Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 SignalingStatus unknownNCT03412643Phase 2
- Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for TransplantationCompletedNCT03402295Phase 3
- Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCTStatus unknownNCT03385096Phase 2/3
- Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple MyelomaStatus unknownNCT03380039Not applicable
- Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic LeukemiaStatus unknownNCT03339700Phase 2
- Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCTStatus unknownNCT03336632Phase 2
- Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple MyelomaStatus unknownNCT03336073Phase 2
- Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/LymphomaCompletedNCT03328104Phase 1
- Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status unknownNCT03321890Phase 2
- Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsStatus unknownNCT03302403Not applicable
- Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBCCompletedNCT03289819Phase 2
- ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016Active, not recruitingNCT03286634Phase 2
- MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast CancerWithdrawnNCT03285607Phase 1
- Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary AmyloidosisStatus unknownNCT03252600Phase 2
- The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)CompletedNCT03242460Phase 2
- Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT03241940Phase 1
- Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL AmyloidosisCompletedNCT03236792Phase 1/2
- Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by ChemiotherapyTerminatedNCT03225924Phase 1/2
- Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA NephropathyStatus unknownNCT03218852Phase 4
- IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma PatientsCompletedNCT03203005Phase 1/2
- Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast CancerTerminatedNCT03202446Phase 3
- Cyclophosphamide Versus Mycophenolate Mofetil in Lupus NephritisCompletedNCT03200002Phase 2
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03197571Phase 1/2
- Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple MyelomaWithdrawnNCT03191981Phase 1/2
- Risk Adapted Therapy in Diffuse Large B Cell LymphomaStatus unknownNCT03188198Phase 2
- MUK Nine b: OPTIMUM Treatment ProtocolActive, not recruitingNCT03188172Phase 2
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnNCT03175666Phase 1/2
- Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia MajorStatus unknownNCT03171831Phase 4
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnNCT03169738Phase 1/2
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03167177Phase 1/2
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnNCT03167164Phase 1/2
- Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell LymphomasCompletedNCT03161054Phase 2
- A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2Active, not recruitingNCT03152318Phase 1
- The p53 Colorectal Cancer TrialTerminatedNCT03149679Phase 2
- Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic CyclophosphamideCompletedNCT03139851Phase 2
- Cyclophosphamide and Alemtuzumab In LymphomaTerminatedNCT03132584Phase 1
- Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid LeukemiaTerminatedNCT03126864Phase 1
- Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary MyelofibrosisActive, not recruitingNCT03118492Phase 1
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
- BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple MyelomaStatus unknownNCT03093168Phase 1
- Haploidentical Stem Cell Transplantation Using Post-Transplant CyclophosphamideTerminatedNCT03088709Phase 2
- Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)WithdrawnNCT03088293Phase 3
- Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaActive, not recruitingNCT03068624Phase 1
- Clinical Trial Evaluating Metronomic Chemotherapy in Patients With Metastatic OsteosarcomaStatus unknownNCT03063983Phase 2
- Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk NeuroblastomaStatus unknownNCT03061656Phase 2
- PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated MalignanciesStatus unknownNCT03044743Phase 1/2
- A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing ToxicityCompletedNCT03032783Phase 2
- A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)Status unknownNCT03030976Phase 1
- Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingNCT03029403Phase 2
- A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast CancerCompletedNCT03017404Not applicable